Reading Between the Peaks: What an HPLC Purity Figure Can and Cannot Certify in a Lab-to-Lab Protocol Transfer
When a protocol moves between laboratories, an HPLC purity figure often travels with more authority than it can support. A receiving group may see “99% pure” on a certificate or catalogue page and treat it as a universal clearance mark. In practice, that number is a narrow analytical statement about one chromatographic measurement, made under one set of conditions, on one sample. It is useful, but it is not a complete description of identity, formulation, batch lineage or suitability for a specific in-vitro workflow. For research groups and materials managers, the task is to separate what the figure certifies from what still needs to be checked before the transfer is accepted.
What a Reported HPLC Purity Percentage Actually Measures
In high-performance liquid chromatography, a purity figure is usually derived from integrated peak area. The laboratory compares the area of the main peak with the total area of detected peaks and expresses the result as a percentage. That makes the figure a relative chromatographic measure, not an absolute measure of chemical purity by mass. A sample reported at 99% may contain one per cent of detected impurities, but it may also contain material that the method does not detect, co-elutes with the main peak, or falls below the integration threshold. The number is therefore best read as “what this method saw under these conditions”, not as a complete compositional audit.
Method dependence matters greatly in a protocol transfer. Column chemistry, mobile phase, gradient, detection wavelength, sample preparation, injection volume and integration settings can all change the result. A receiving laboratory may use a different column or a slower gradient and resolve additional peaks that the sending laboratory’s method did not separate. That does not automatically mean the material has degraded or that the supplier’s figure was false. It means the two laboratories are asking slightly different analytical questions. The transfer discussion should therefore include the method context behind the figure, not just the headline percentage.
An HPLC purity figure also leaves several categories untouched. It does not confirm identity, counter-ion composition, water content, residual solvents, excipient content, heavy-metal status or endotoxin status. Some of these may be covered by other documents or tests, but the purity percentage alone does not cover them. Research Sciences’ homepage currently publishes lines such as “≥99% Verified Purity” and “UK Research Materials Over 99.1% Purity”, alongside “CoAs Janoshik Analytical Reports”. These are site-level published statements, not a substitute for the batch-specific CoA, and they should be reconfirmed on the live site and against the document that accompanies the actual vial.
Identity, Formulation and Batch Lineage Are Separate Questions
A purity figure can describe how much of the detected material sits in one peak, but it does not tell the receiving group whether that peak is the intended peptide. Identity is a separate analytical question. The CoA should be opened and checked for the identity statement associated with the batch, not simply scanned for a purity number. If identity documentation is missing, incomplete or disconnected from the vial reference, the receiving laboratory should treat the material as analytically unverified for that transfer, even if the chromatogram looks clean.
Formulation is another separate issue. The supplier’s FAQ notes that peptides contain trace amounts of mannitol as an excipient, used for vial presentation, lyophilisation stability and solubility. A peptide purity percentage does not describe the excipient or the full formulated content of the vial. Handling notes also need to travel with the protocol: lyophilised materials are stored at –20°C or below, sealed with desiccant and protected from moisture, heat and light; repeated freeze–thaw cycles should be avoided; reconstituted material is less stable and should be kept at 2–8°C for short-term laboratory use. These are in-vitro laboratory handling points only. The materials are not for human or veterinary use, and they are not medicines, medical devices, injectables, treatments or food supplements under UK law.
Batch lineage is equally important. The supplier’s FAQ explains that restocked products may carry the same Internal Test Reference as earlier stock. An ITR links to associated sample testing reports, but it does not confirm that separate deliveries come from the same production lot or have had separate independent testing. Vial cap colours and other packaging may vary; cap colour is not an indicator of identity, analytical quality or manufacturing origin. Labels use a reference format combining SKU code and expiry date, for example BPC10-03/27, and that reference should be quoted when contacting the shop about documentation. When replacement stock is being considered from a UK catalogue, including Uk peptides supplied by Research Sciences, the receiving group should still open the batch CoA and compare the method, identity statement and storage notes before accepting the transfer.
A Practical Transfer Checklist for Documents, Handling and In-Lab Verification
For a materials manager, the first rule is not to transfer a protocol on the strength of a catalogue-level purity figure. Request the batch CoA, match it to the vial label reference, and check whether the document supports the claims being relied upon. If the supplier publishes “≥99% Verified Purity” or lists Janoshik Analytical Reports, treat those as published lines to reconfirm rather than as batch evidence in themselves. Ask whether a chromatogram or method summary is available for the batch. If it is not, record that limitation in the transfer note so the receiving laboratory knows the figure is a summary claim rather than a fully contextualised result.
Transport and storage history should be reviewed alongside the analytical documents. Temperature-aware storage and tracked domestic fulfilment are useful operational signals, but they do not replace a review of the actual receipt condition. The receiving laboratory should confirm that lyophilised vials arrived sealed and protected from moisture, heat and light, and should record any deviation. Once in the laboratory, the storage and handling rules should be written into the protocol: –20°C or below for lyophilised stock, avoidance of repeated freeze–thaw cycles, and 2–8°C for short-term laboratory use after reconstitution. All reconstitution and handling language should remain inside an in-vitro laboratory workflow. The materials are not for human or veterinary use.
In-laboratory verification should be proportional to the protocol’s needs. A receiving group may run a suitability check with its own HPLC method, or use an orthogonal identity check where the protocol requires it. If the local method resolves extra peaks, the group should document the method differences before concluding that the batch is unsuitable. For reconstitution steps, record the diluent volume and target assay concentration in the in-vitro protocol; the Research Sciences reconstitution calculator is described for laboratory research use only and must not be used for human or veterinary dosing. The useful distinction for the transfer record is threefold: which claims are supplier-published, which are batch-documented, and which have been locally verified. Keeping those categories separate prevents one HPLC purity figure from becoming an unexamined assumption in the receiving laboratory.
Novgorod industrial designer living in Brisbane. Sveta explores biodegradable polymers, Aussie bush art, and Slavic sci-fi cinema. She 3-D prints coral-reef-safe dive gear and sketches busking musicians for warm-up drills.